EGFR and non-small cell lung carcinoma: Indeed, in the placebo-controlled MISSION study, sorafenib significantly improved both PFS (2.7 months for sorafenib versus 1.4 months for placebo) and OS (13.9 versus 6.5 months) in NSCLC patients with mutant EGFR, whereas no difference was observed when the whole cohort of patients was analyzed28.